Table I.
naïve | Heterogeneity in B cell memory | ||||||
---|---|---|---|---|---|---|---|
Memory B cells | Switched or Unswitched Memory B Cells | ||||||
IgM | IgM+ | IgG+ | IgA+ | LLPC | PD-L2loCD80lo | PD-L2hiCD80hi | |
developmental route | n.d. | pre- & post-GC | pre- & post-GC | post-GC | post-GC | not known | not known |
tissue tropism | recirculating | recirculating | recirculating | Mucosal | bone marrow and mucosal | not known | not known |
S0HM | none | low or high | low or high | high | low or high | low | high |
life span | brief | indefinite | decays | not known | indefinite | indefinite | indefinite |
propensity for effector cell fates | germinal center ≫ plasma cell | limited by presence of high affinity antibody | plasma cell ≫ germinal center | plasma cell ≫ germinal center | Inert | germinal center ≫ plasma cell | plasma cell ≫ germinal center |
repertoire | broad/low affinity | archival? | broad/low affinity | unknown | narrow/high affinity | broad/low affinity | not known |
CD19 expression | high | high | high | high | low/absent | high | high |
CD20 expression | high | high | high | high | low/absent | high | high |
BAFFR expression | high | high | high | high | high | high | high |
BCMA expression | low/absent | low/absent | low/absent | low/absent | high | low/absent | low/absent |
Potential therapeutics | Alemtuzumab Rituximab |
Belimumab Atacicept Rituximab |
Belimumab Atacicept Rituximab |
Belimumab Atacicept Rituximab |
Bortezomib Atacicept IVIG Plasmaphoresis |
Belimumab Atacicept Rituximab |
Belimumab Atacicept Rituximab |